The depot of buprenorphine decanoate produced a dose-related long-lasting antinociceptive effect in guinea pigs

Acta Anaesthesiologica Taiwanica

Volumn 44, Issue 3, 2006, Pages 161-168

  Wu, Su Zhen ^a   Liu, Kuo Sheng ^b   Chu, Koung Shing ^c   Cheng, Kuang I ^c   Kuei, Chun Hsiung ^b   Wang, Jhi Joung ^a   Tzeng, Jann Inn ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Analgesics; Antinociception; Buprenorphine; Long acting preperations; Prodrugs

Indexed keywords

ANTINOCICEPTIVE AGENT; BUPRENORPHINE; BUPRENORPHINE DECANOATE; LONG ACTING DRUG; NARCOTIC ANALGESIC AGENT; OIL; PRODRUG; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; MALE; NONHUMAN; PAIN;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; INJECTIONS, INTRAMUSCULAR; MALE; PAIN;

EID: 33749063973     PISSN: 02541319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Johnson RE, Fudala PJ, Payne R: Buprenorphine: considerations for pain management. J Pain Symptom Manage 29:297-326, 2005.
2. Sorge J, Sittl R: Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 26: 1808-1820, 2004.
3. Barnett PG, Rodgers JH, Bloch DA: A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 96:683-690, 2001.
4. Davids E, Gastpar M: Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 14:209-216, 2004.
5. Liu KS, Tzeng JI, Chen YW, Huang KL, Kuei CH, Wang JJ: Novel depots of burenorphine prodrugs have a long-acting antinociceptive effect. Anesth Analg 102:1445-1451, 2006.
6. Roy SD, Roos E, Sharma K: Transdermal delivery of buprenorphine through cadaver skin. J Pharm Sci 83:126-130, 1994.
7. Stinchcomb AL, Dua R, Paliwal A, Woodard RW, Flynn GL: A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm Res 12:1526-1529, 1995.
8. Montagne-Clavel J, Oliveras JL: The "plantar test" apparatus (Ugo Basile Biological Apparatus), a controlled infrared noxious radiant heat stimulus for precise withdrawal latency measurement in the rat, as a tool for humans? Somatosens Mot Res 13:215-223, 1996.
9. Liu SY, Liu KS, Kuei CH, Tzeng JI, Ho ST, Wang JJ: Simultaneous determination of buprenorphine and its prodrug, buprenorphine propionate, by high performance liquid chromatography with fluorescence detection: application to pharmacokinetic studies in rabbits. J Chromatogr Biomed Appl 818:233-239, 2005.
10. Lerman J: Study design in clinical research: sample size estimation and power analysis. Can J Anaesth 43:184-191, 1996.
11. Gutstein HB, Akil H: Opioid analgesics. In: Hardman JG, Limbird LE, Goodman GA. (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 10th edn. New York: McGraw-Hill, p569-620, 2001.
12. Bulka A, Kouya PF, Bottiger Y, Svensson JO, Xu XJ, Wiesenfeld-Hallin Z: Comparison of the antinociceptive effect of morphine, methadone, buprenorphine and codeine in two substrains of Sprague-Dawley rats. Eur J Pharmaco 492: 27-34, 2004.
13. 3 analgesia. Brain Res 744:41-46, 1997.
14. Que J, Lin LC, Liu SY, Chu CC, Liu KS, Ho ST, Wang JJ: A novel long-acting analgesic: buprenorphine palmitate in rats. Acta Anaesthesiol Taiwanica 43:11-6, 2005.
15. Yang C, Lan KM, Liu KS, Chen YW, Tzeng JI, Ho ST, Wang JJ: The antinociceptive effect of buprenorphine and its long-acting ester buprenorphine benzoate in rats. Acta Anaesthesiol Taiwanica 42:135-139, 2004.
16. Allen LV Jr, Popovich NG, Ansel HC: Introduction to drugs, drug dosage forms, and drug delivery systems: new drug development and approval process. In: Ansel's pharmaceutical dosage forms and drug delivery systems. 8th edn. Philadelphia: Lippincott Williams & Wilkins, p25-66, 2005.
17. Allen LV Jr, Popovich NG, Ansel HC: Sterile dosage forms and delivery systems: parenterals. In: Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. 8th edn. Philadelphia: Lippincott Williams & Wilkins, p443-505, 2005.
18. Allen LV Jr, Popovich NG, Ansel HC: Drug dosage form and drug delivery system design: biopharmaceutic and pharmacokinetics considerations. In: Ansel's pharmaceutical dosage forms and drug delivery systems. 8th edn. Philadelphia: Lippincott Williams & Wilkins, p142-185, 2005.
19. Beresford R, Ward A: Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 33:31-49, 1987.
20. Kamischke A, Venherm S, Ploger D, von Eckardstein S, Nieschlag E: Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 86:303-309, 2001.
21. Buchwald P, Bodor N: Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem 42: 5160-5168, 1999.
22. Testa B, Mayer JM: Introduction: metabolic hydrolysis and prodrug design. In: Hydrolysis in drug and prodrug metabolism: chemistry, biochemistry, and enzymology. Zurich, Switzerland: Verlag Helvetica Chimica Acta, p1-11, 2003.